Tarsus Pharmaceuticals Secures China Approval for TP-03, Triggers $15M Milestone Payment

Key Facts

1China's National Medical Products Administration (NMPA) approved TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.

2The regulatory approval triggers a $15 million milestone payment due to Tarsus Pharmaceuticals.

3The drug is marketed in the United States under the brand name XDEMVY.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that China's National Medical Products Administration (NMPA) has approved TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. The drug is already marketed in the United States under the brand name XDEMVY. This regulatory milestone in China triggers a $15 million milestone payment to Tarsus, providing a significant boost to the company's non-dilutive capital. The expansion into the Chinese market represents a major strategic victory, broadening the global reach of the company's lead product. Investors view this development as a positive fundamental catalyst, combining immediate funding with long-term revenue growth potential. The approval underscores the drug's clinical efficacy and the company's ability to successfully navigate international regulatory landscapes.

Open on chart